Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

BASEL, Switzerland, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross proceeds to Axovant from the offering are expected to be approximately $30,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 of its common shares on the same terms and conditions. The offering is expected to close on December 18, 2018, subject to customary closing conditions.

Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

A shelf registration statement relating to the offered common shares was filed with the Securities and Exchange Commission (SEC), and was declared effective on January 13, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website, located at Copies of the final prospectus supplement and accompanying base prospectus related to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, or by telephone at (212) 518-9658, or by email at

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

About Axovant 
Axovant is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases such as Parkinson's disease, GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and other indications. For more information, visit

SOURCE Axovant Sciences



Tricia Truehart
(631) 892-7014


Lara Yuan
(646) 802-3585